Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
A multicentre, unblinded, randomized phase II trial evaluating Lu-177 vipivotide tetraxetan (6·0–8·5 GBq intravenously every 6 weeks for up to six cycles) or cabazitaxel (20 mg/m2 intravenously every 3 weeks for up to ten cycles) in men with metastatic castration-resistant prostate cancer for whom cabazitaxel was considered the next appropriate standard treatment.
Primary outcome measures:
Prostate Specific Antigen response rate
The authors concluded that Lu-177 vipivotide tetraxetan, compared with [cabazitaxel](brain://ry1V8L7fuUeMhbj…